Cargando…
Bone loss and the aromatase inhibitors
The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopau...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361688/ https://www.ncbi.nlm.nih.gov/pubmed/16100521 http://dx.doi.org/10.1038/sj.bjc.6602691 |
_version_ | 1782153275122909184 |
---|---|
author | Lester, J Coleman, R |
author_facet | Lester, J Coleman, R |
author_sort | Lester, J |
collection | PubMed |
description | The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk. Ongoing clinical trials are favouring the use of the aromatase inhibitors over tamoxifen and this may advocate greater use of these drugs in the future. Strategies for the identification and management of treatment-induced bone loss are currently being defined. |
format | Text |
id | pubmed-2361688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23616882009-09-10 Bone loss and the aromatase inhibitors Lester, J Coleman, R Br J Cancer Aromatase Inhibitors–Past, Present and Future The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk. Ongoing clinical trials are favouring the use of the aromatase inhibitors over tamoxifen and this may advocate greater use of these drugs in the future. Strategies for the identification and management of treatment-induced bone loss are currently being defined. Nature Publishing Group 2005-08 2005-08-15 /pmc/articles/PMC2361688/ /pubmed/16100521 http://dx.doi.org/10.1038/sj.bjc.6602691 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Aromatase Inhibitors–Past, Present and Future Lester, J Coleman, R Bone loss and the aromatase inhibitors |
title | Bone loss and the aromatase inhibitors |
title_full | Bone loss and the aromatase inhibitors |
title_fullStr | Bone loss and the aromatase inhibitors |
title_full_unstemmed | Bone loss and the aromatase inhibitors |
title_short | Bone loss and the aromatase inhibitors |
title_sort | bone loss and the aromatase inhibitors |
topic | Aromatase Inhibitors–Past, Present and Future |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361688/ https://www.ncbi.nlm.nih.gov/pubmed/16100521 http://dx.doi.org/10.1038/sj.bjc.6602691 |
work_keys_str_mv | AT lesterj bonelossandthearomataseinhibitors AT colemanr bonelossandthearomataseinhibitors |